Musculoskeletal Peptide Safety Review
AOD-9604 positioned in the framework of unapproved peptides used for joint repair.
[1]A synthetic peptide corresponding to the lipolytic C-terminal fragment of human growth hormone (177 to 191 sequence with N-terminal tyrosine for stability). Originally developed by Monash University and licensed to Metabolic Pharmaceuticals as an anti-obesity agent.
At a glance
- Type
- Synthetic peptide, lipolytic C-terminal fragment of human growth hormone (177 to 191 sequence with N-terminal tyrosine for stability)
- Origin
- Monash University / Metabolic Pharmaceuticals
- Design goal
- Fat-burning effects of GH without glycemic, IGF-1, or organ growth effects
- Clinical history
- Advanced through Phase 2 trials for obesity; current focus on cartilage and joint repair
- Route
- Subcutaneous
- WADA
- Banned for competitive athletes
What the research supports
AOD-9604's evidence base centers on GH-fragment lipolytic mechanism without GH receptor activation and recent orthopedic application research.
Therapeutic Peptides in Orthopaedics
Reviewed within orthopedic peptide applications alongside other GH-derived and recovery peptides.
[2]Beta-3 Adrenergic Lipolysis
Lipolytic activity through beta-3 adrenergic receptor pathway, distinct from GH receptor signaling.
No GH Receptor Activation
No IGF-1 elevation, no glucose effects, no organ growth, no skeletal effects; cleanest GH-derived lipolytic profile.
Summary of key findings
GH Lipolytic Effects Without GH Receptor Activation
The key differentiator: fat burning without metabolic and growth side effects of full-length GH.
Failed Phase 2b for Obesity Monotherapy
Set patient expectations honestly: not an FDA-approved obesity drug and unlikely to drive dramatic weight loss alone.
Research Center of Gravity is Joint Repair
Current active research is in osteoarthritis and chondroprotective applications, not obesity.
Favorable Safety Profile
One of the most favorable safety profiles in the peptide space because the molecule does not activate the GH receptor.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Subcutaneous Protocol
- Standard protocol: 0.3 mg (300 mcg) subcutaneous 1x daily fasted in the morning, at least 30 minutes prior to food and drink.
- Stacking
- Pairs commonly with CJC-1295, Ipamorelin, Sermorelin in body composition protocols (synergy claim is more theoretical than evidence-based). For joint applications combines with BPC-157 and TB-500.
- Cycling
- 4 months on, 1 month off.
- Timing
- AM fasted dosing preferred to maximize lipolytic window.
Protocol reference
| Form factor | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| AOD-9604 0.3 mg / 300 mcg | 0.3 mg | SC | 1x daily fasted AM | 30 minutes prior to food. 4 months on, 1 month off. |
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
AOD-9604 is the cleanest GH-derived lipolytic peptide. It retains the fat burning effects of GH without the metabolic and growth side effects. Set patient expectations honestly: the Phase 2b obesity trial did not meet primary endpoints, which is why it is not an FDA-approved obesity drug. As monotherapy, it is unlikely to drive dramatic weight loss. The current research center of gravity is joint and cartilage repair, not obesity. Safety profile is one of the most favorable in the peptide space because the molecule does not activate the GH receptor. Pairs commonly with growth hormone secretagogues in body composition protocols, though the synergy claim is more theoretical than evidence-based. For joint applications, often combined with BPC-157 and TB-500 in regenerative protocols. Banned by WADA.
Lipolytic Without GH Effects
Fat-burning mechanism without IGF-1, glucose, or organ growth side effects
Joint and Cartilage Repair
Current research center of gravity beyond original obesity indication
Stack Adjunct
Pairs with GH secretagogues for body composition and with BPC-157/TB-500 for joint applications
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Mendias and Awan, 2026 Peptide Therapies for Musculoskeletal Injuries Safety Review
- 2Rahman et al., 2026 Therapeutic Peptides in Orthopaedics
- 3AOD-9604 Phase 2 Obesity Clinical TrialCitation under review
- 4Kwon and Park, 2015 AOD-9604 Chondroprotective Preclinical Data
Regulatory status, cautions and contraindications
Pregnancy and Lactation
Insufficient data; avoid use during pregnancy and lactation.
Active Malignancy
Theoretical caution though no GH receptor activation reduces concern. Consult a licensed provider.
WADA Status
Banned for competitive athletes. Not for use by individuals subject to anti-doping regulations.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.